Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma

BACKGROUND: Despite advances in combined modality therapy, outcomes in head and neck squamous cell cancer (HNSCC) remain dismal with five-year overall survival rates of less than 50%. Prognostic biomarkers are urgently needed to identify patients with a high risk of death after initial curative trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sailer, Verena, Gevensleben, Heidrun, Dietrich, Joern, Goltz, Diane, Kristiansen, Glen, Bootz, Friedrich, Dietrich, Dimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472307/
https://www.ncbi.nlm.nih.gov/pubmed/28617833
http://dx.doi.org/10.1371/journal.pone.0179412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472307/
https://www.ncbi.nlm.nih.gov/pubmed/28617833
http://dx.doi.org/10.1371/journal.pone.0179412

Ejemplares similares